Methods of treating lupus based on antibody affinity and...

Details Methods of treating lupus based on antibody affinity and... Methods of treating lupus based on antibody affinity and...

2006-07-25

2006-07-25

Guzo, David (Department: 1636)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C523S001000, C523S001000

Reexamination Certificate

active

07081242

ABSTRACT:
The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient.

REFERENCES:
patent: 5126131 (1992-06-01), Dintzis et al.
patent: 5162515 (1992-11-01), Conrad et al.
patent: 5268454 (1993-12-01), Barstad et al.
patent: 5276013 (1994-01-01), Conrad et al.
patent: 5370871 (1994-12-01), Dintzis et al.
patent: 5391785 (1995-02-01), Jones et al.
patent: 5470570 (1995-11-01), Taylor et al.
patent: 5487890 (1996-01-01), Taylor et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5606047 (1997-02-01), Coutts et al.
patent: 5633395 (1997-05-01), Coutts et al.
patent: 5726329 (1998-03-01), Jones et al.
patent: 5786512 (1998-07-01), Jones et al.
patent: 5817752 (1998-10-01), Yu
patent: 5856464 (1999-01-01), Livingston
patent: 5874409 (1999-02-01), Victoria et al.
patent: 5874552 (1999-02-01), Jones et al.
patent: 5879679 (1999-03-01), Taylor et al.
patent: 6022544 (2000-02-01), Dintzis et al.
patent: 6060056 (2000-05-01), Coutts et al.
patent: 6207160 (2001-03-01), Victoria et al.
patent: 6340460 (2002-01-01), Dintzis
patent: 6362254 (2002-03-01), Harris et al.
patent: 6375951 (2002-04-01), Dintzis
patent: 6399578 (2002-06-01), Jack et al.
patent: 6458953 (2002-10-01), Jones
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6858210 (2005-02-01), Marquis et al.
patent: 2001/0010808 (2001-08-01), Yagi et al.
patent: 2001/0010818 (2001-08-01), Engle et al.
patent: 2002/0082400 (2002-06-01), Coutts et al.
patent: 2002/0103343 (2002-08-01), Taylor et al.
patent: 2002/0107389 (2002-08-01), Coutts et al.
patent: 2002/0110535 (2002-08-01), Jones
patent: 2002/0187156 (2002-12-01), Dintizis et al.
patent: 2003/0077273 (2003-04-01), Linnik et al.
patent: 2003/0103990 (2003-06-01), Coutts et al.
patent: 2003/0114405 (2003-06-01), Linnik et al.
patent: 2003/0162953 (2003-08-01), Coutts et al.
patent: 2004/0208864 (2004-10-01), Strand et al.
patent: 2004/0224366 (2004-11-01), Jones et al.
patent: 2004/0258683 (2004-12-01), Linnik et al.
patent: 2005/0004351 (2005-01-01), Marquis et al.
patent: 2005/0026856 (2005-02-01), Coutts et al.
patent: 2005/0031635 (2005-02-01), Coutts et al.
patent: 0 438 259 (1991-07-01), None
patent: 0 642 798 (1995-03-01), None
patent: 0 743 856 (1996-11-01), None
patent: WO 91/10426 (1991-07-01), None
patent: WO 92/05801 (1992-04-01), None
patent: WO 92/13558 (1992-08-01), None
patent: WO 93/02093 (1993-02-01), None
patent: WO 95/07073 (1995-03-01), None
patent: WO 95/22977 (1995-08-01), None
patent: WO 96/40197 (1996-12-01), None
patent: WO 96/40708 (1996-12-01), None
patent: WO 97/46248 (1997-12-01), None
patent: WO 97/46251 (1997-12-01), None
patent: WO 99/40434 (1999-08-01), None
patent: WO 99/64595 (1999-12-01), None
patent: WO 00/15259 (2000-03-01), None
patent: WO 00/33887 (2000-06-01), None
patent: WO 00/34231 (2000-06-01), None
patent: WO 00/34296 (2000-06-01), None
patent: WO 00/75105 (2000-12-01), None
patent: WO 01/41813 (2001-06-01), None
patent: WO 01/45669 (2001-06-01), None
patent: WO 01/80883 (2001-11-01), None
patent: WO 01/93914 (2001-12-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO 02/092011 (2002-11-01), None
patent: WO 2004/060320 (2004-07-01), None
Jones et al. Immunospecific Reduction of Antioligonucleotide Antibody Forming Cell with a Tetrakis-oligonucleotide Conjugate, a Therapeutic Candidate for the Treatment of Lupus Nephritis. J. Med. Chem. 1995, vol. 38, No. 12, pp. 2138-2144.
Bootsma, H. et al. (1995). “Prevention of Relapses in Systematic Lupus Erythematosus”,Lancet, 345:1595-1599.
Borel, Y. et al. (1990) “A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens”J. Immunol. Methods126:159-168.
Borel, Y. et al. (1995) “Food Allergens Transformed into Tolerogens”Int. Arch. Allergy Immunol. 107:264-267.
Borel, Y. et al. (1996) “Parenteral and Oral Administration of Tolerogens: Protein-IgG Conjugates”Ann. N.Y. Acad. Sci. 778:80-87.
Borg, E. J. et al. (1990). “Measurement of Increases in Anti-Double-Stranded DNA Antibody Levels as a Predictor of Disease Exacerbation in Systemic Lupus Erythematosus”,Arthritis Rheumatism. 33:634-643.
Coutts, S. M. et al. (1996). “Pharmacological Intervention in Antibody Mediated Disease”,Lupus5:158-159.
Dintzis, R. Z. et al. (1983). “Studies on the Immunogenicity and Tolerogenicity of T-Independent Antigens”,The Journal of Immunology13(5):2196-2203.
Dintzis, R. Z. et al. (1989). “The Immunogenicity of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence”,The Journal of Immunology143:1239-1244.
Dumas, V. et al. (1995). “Induction of Tolerance by Administration of Hapten-Immunoglobin Conjugates is Assoicated with Decreased IL-2 and IL-4 Production”,Arch. Dematol.Res., 287:123-128.
Foster, M. H. et al. (1993). “Biology of Disease Nephritogenic Autoantibodies in Systematic Lupus Erythematosus: Immunochemical Properties, Mechanisms of Immune Deposition, and Genetic Origins”,Laboratory Investigation, 69(5):494-507.
Jones, D. et al. (1994). “Conjugates of Double -Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyann: a Model for Treating Systematic Lupus Erythematosus”,Bioconjugate Chemistry5:390-399.
Jones, D. et al. (1995). “Immunospecific Reduction of Antioligonucleotide Antibody-Forming Cells with a Tetrakis-Oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis”,J. Med. Chem. 38:2138-2144.
Morimoto, C. et al. (1982). “A Defect of Immunoregulatory T Cell Subsets in Systematic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody”,The Journal of Immunology139:1960-1965.
Plunkett, M. L. et al. (1995). “LJP 394: A Novel Clinical Candidate for the Treatment of Lupus Nephritis”,Lupus4:S99.
Seleznick, M. J. et al. (1991). “Variables Associated with Decreased Survival in Systematic Lupus Erythematosus”,Seminars in Arthritis and Rheumatism21:73-80.
Sem, D. S. et al. (1999). “Antibody Affinities and Relative Titers in Polyclonal Population: Surface Plasmon Resonance Analysis of Anti-DNA Antibodies”,Archives of Biochemistry and Biophysics1:372(1):62-68.
Weisman, M. H. et al. (1997). “Reduction in Circulating dsDNA Antibody Titer after Administration of LJP 394”,The Journal of Rheumatology24:314-318.
U.S. Appl. No. 10/748,541, filed Dec. 29, 2003, Strand et al.
U.S. Appl. No. 10/814,555, filed Mar. 30, 2004, Linnik et al.
Ferguson, P. J. et al. (1995). “Antigen-Based Heteropolymers Facilitate, Via Primate Erythrocyte Complement Receptor Type 1, Rapid Erythrocyte Binding of an Autoantibody and Its Clearance From The Circulation in Rhesus Monkeys,”The Journal of Immunology155:339-347.
Ferguson, P. J. et al. (1994). “Antigen-Based Heteropolymers (AHP): A Potential Therapeutic to Bind and Clear Autoantibodies Via Erythrocyte (E) CR1,”Arthritis&Rheumatism37(9 Suppl.) p. S406, Abstract No. 1467.
Aharoni, A. et al., (1993) “Characterization of a multisubunit human protein which selectively binds single stranded d(GA)nand d(GT)nsequence repeats in DNA”Nucl. Acid. Res. 21(22):5221-5228.
McNeeley, P.A. (2001). “Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients,”Lupus10:526-532.
Jones, D. et al. (May-Jun. 1999). “Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response”Bioconjugate Chemistry10(3):480-488.
Jones, D. et al. (2000). “A Convenient Synthesis of N-(tert-butyloxycarbonyl) Aminooxy Ether

Affiliated with

Also associated with

Rating

Methods of treating lupus based on antibody affinity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating lupus based on antibody affinity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating lupus based on antibody affinity and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3559071